Bryan Unger: 1st Patient Has Been Enrolled in NuvOx Therapeutics’ Phase IIb NOVEL Trial
Bryan Unger, Director of Business Development at Microvascular Therapeutics, reposted from NuvOx Therapeutics on LinkedIn:
”Proud to share that the first patient has been enrolled in NuvOx Therapeutics’ Phase IIb NOVEL trial evaluating NanO₂™ in acute ischemic stroke due to large vessel occlusion.
Stroke is one of the leading drivers of long-term disability and healthcare costs, with lifelong care representing a substantial burden for patients, families, and health systems.
Our Phase IIa data for NanO₂ showed strong potential in reducing this burden.
Reaching the first patient enrolled is a critical milestone.
We are grateful to the clinical teams and partners who are advancing this work.”
Quoting NuvOx Therapeutics‘s post:
”We have enrolled the first patient in NuvOx Therapeutics’ Phase IIb NOVEL trial evaluating NanO₂™ in acute ischemic stroke due to large vessel occlusion (LVO).
NOVEL is a multicenter, randomized, placebo-controlled study funded by the NIHR (National Institute for Health and Care Research)–MRC EME Programme, and co-sponsored by the University of Glasgow and NHS Greater Glasgow and Clyde.
This milestone advances NanO₂, designed to rapidly improve tissue oxygenation, toward addressing one of the most severe and costly forms of stroke.
We thank our clinical collaborators and funding partners as we activate additional sites and accelerate enrollment.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation
-
Mar 16, 2026, 17:42Mohamed Sherif Salem: Turning 2026 KDIGO Complexity into Bedside Clarity
-
Mar 16, 2026, 17:39Julie Cardoso: What Happens to Venous Valves When a Blood Clot Forms?
-
Mar 16, 2026, 17:38Nasir Jamal: Blood Transfusion Criteria and Hemodialysis Thresholds in ESRD Patients
-
Mar 16, 2026, 17:37Octavio Cosín Sales: Understanding the Influence of Systemic Factors on Chronic Venous Insufficiency
-
Mar 16, 2026, 17:35Shiny K. Kajal: From Simple Calcium Chelation to Full-Blown Red Cell Metabolic Engineering
-
Mar 16, 2026, 17:12Cold-Stored vs Room-Temperature Platelets in Trauma-Induced Coagulopathy – JTH
-
Mar 16, 2026, 17:10Arturo Cesaro: First Meta-Analysis on the Vascular Protective Role of Semaglutide in PAD